Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Molecular Partners AG ADR

Healthcare US MOLN

4.0999USD
0.17(4.32%)

Last update at 2026-06-05T20:00:00Z

Day Range

4.034.10
LowHigh

52 Week Range

3.327.32
LowHigh

Fundamentals

  • Previous Close 3.93
  • Market Cap124.90M
  • Volume1903
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-60.18000M
  • Revenue TTM7.04M
  • Revenue Per Share TTM0.21
  • Gross Profit TTM 138.85M
  • Diluted EPS TTM-1.94

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 117.85M -63.78300M -62.77500M -36.27100M -37.03600M
Minority interest - - - - -
Net income 117.85M -63.78500M -62.76400M -36.28800M -37.03600M
Selling general administrative 21.82M 16.91M 11.03M 13.16M 9.46M
Selling and marketing expenses - - 0.06M 5.23M -
Gross profit 189.56M 9.33M 9.34M 20.38M -5.24700M
Reconciled depreciation 2.39M 2.56M 2.89M 2.47M 0.92M
Ebit 116.61M -63.41800M -58.32600M -36.66000M -37.19200M
Ebitda 120.13M -60.76200M -55.10400M -32.66500M -36.26800M
Depreciation and amortization 3.52M 2.66M 3.22M 4.00M 0.92M
Non operating income net other - - - - -
Operating income 116.61M -63.41800M -58.32600M -36.66000M -37.41000M
Other operating expenses 72.94M 72.75M 67.67M 57.04M 47.77M
Interest expense 0.60M 0.55M 0.27M 0.03M 0.59M
Tax provision 0.00000M 0.00200M -0.01100M 0.02M 0.00000M
Interest income 1.14M 0.10M 0.37M 1.60M 0.69M
Net interest income 0.52M -0.45700M 0.06M 1.50M 0.59M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.24000M 0.00200M -0.01100M 0.02M -0.59100M
Total revenue 189.56M 9.33M 9.34M 20.38M 10.36M
Total operating expenses 72.94M 72.75M 67.67M 57.04M 47.77M
Cost of revenue - - - - 15.60M
Total other income expense net 1.24M -0.36500M -4.44900M 0.39M -0.21800M
Discontinued operations - - - - -
Net income from continuing ops 117.85M -63.78500M -62.76400M -36.28800M -37.03600M
Net income applicable to common shares 117.85M -63.78500M -62.76400M -36.28800M -37.03600M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 198.35M 262.26M 172.67M 187.55M 104.94M
Intangible assets 0.21M 0.27M 0.33M 0.35M 0.77M
Earning assets - - - - -
Other current assets 3.83M 3.91M 92.38M 4.09M 4.84M
Total liab 21.92M 27.09M 65.38M 80.33M 50.80M
Total stockholder equity 176.43M 235.17M 107.29M 107.22M 54.14M
Deferred long term liab - - - - -
Other current liab 8.46M 8.65M 12.50M 10.74M 7.01M
Common stock 3.63M 3.60M 3.23M 2.92M 2.16M
Capital stock 3.63M 3.60M 3.23M 2.92M 2.16M
Retained earnings -191.75500M -127.78000M -250.95000M -195.17400M -130.87000M
Other liab - 6.19M 13.66M 16.62M 20.91M
Good will - - - - -
Other assets - - - - 5.06M
Cash 186.89M 87.95M 71.81M 133.72M 75.71M
Cash and equivalents - - - - -
Total current liabilities 14.42M 17.25M 46.87M 57.67M 28.61M
Current deferred revenue 4.33M 6.41M 28.31M 42.95M 18.31M
Net debt -183.23700M -83.09600M -65.77400M -126.50300M -73.16700M
Short term debt 1.21M 1.20M 1.19M 1.18M 1.27M
Short long term debt - - - - -
Short long term debt total 3.65M 4.85M 6.04M 7.22M 2.54M
Other stockholder equity 364.55M 360.32M 355.01M 299.48M 182.85M
Property plant equipment - 7.24M 8.15M 9.39M 4.24M
Total current assets 192.46M 254.75M 164.19M 177.81M 99.92M
Long term investments - - - - -
Net tangible assets - 234.90M 106.96M 106.87M 53.37M
Short term investments 119.58M 161.20M 61.00M 40.00M 19.37M
Net receivables 1.75M 1.70M 25.73M 2.84M 2.55M
Long term debt - - - - -
Inventory - - -86.72600M - -
Accounts payable 0.41M 1.00M 4.86M 2.80M 2.02M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M -0.98100M - -10.66200M -8.88100M
Additional paid in capital - - - - -
Common stock total equity - - - 2.92M 2.16M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.21M - 0.00100M - -
Deferred long term asset charges - - - - -
Non current assets total 5.89M 7.51M 8.48M 9.73M 5.01M
Capital lease obligations 3.65M 4.85M 6.04M 7.22M 2.54M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -101.12100M -21.00000M -20.63200M -19.36800M 9.74M
Change to liabilities -30.52900M -8.99500M 20.95M -20.65300M 40.66M
Total cashflows from investing activities -101.12100M -22.23700M -21.74600M -19.83600M 9.61M
Net borrowings -1.18900M -1.17900M -1.25100M -1.23700M -1.23700M
Total cash from financing activities -1.57000M 50.58M 113.20M -0.22700M 0.39M
Change to operating activities -0.74500M -2.29900M 2.08M 1.27M -0.05300M
Net income 117.85M -63.78500M -62.76400M -36.28800M -37.03600M
Change in cash 16.13M -61.90800M 58.01M -23.24600M -32.35800M
Begin period cash flow 71.81M 133.72M 75.71M 98.96M 131.32M
End period cash flow 87.95M 71.81M 133.72M 75.71M 98.96M
Total cash from operating activities 118.57M -90.95300M -28.98300M -1.18900M -42.47400M
Issuance of capital stock 0.00000M 51.49M 113.61M 1.01M 0.39M
Depreciation 2.39M 2.56M 2.89M 2.47M 0.92M
Other cashflows from investing activities 0.49M 0.07M 0.57M 1.40M 0.73M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 25.26M -23.37400M -0.55200M 49.57M -50.83000M
Sale purchase of stock -0.63100M - - - -
Other cashflows from financing activities 0.25M 0.27M 0.84M -19.83600M 9.61M
Change to netincome 4.33M 4.93M 8.41M 2.44M 3.86M
Capital expenditures 1.42M 1.31M 1.68M 1.86M 0.87M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -6.01000M -34.66800M 22.49M 30.19M 0.13M
Stock based compensation 5.09M 4.08M 2.93M 2.44M 3.72M
Other non cash items -0.75300M 0.85M 5.49M -0.01600M -10.72900M
Free cash flow 117.15M -92.26000M -30.66600M -3.05300M -43.34100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MOLN
Molecular Partners AG ADR		 0.17 4.32% 4.10 - 1.78 18.45 0.67 11.08 1.23
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Molecular Partners AG ADR

Wagistrasse 14, Schlieren, Switzerland, 8952

Key Executives

Name Title Year Born
Dr. Patrick Amstutz Ph.D. Co-Founder, CEO, Member of Management Board & Director 1975
Dr. Michael Tobias Stumpp Ph.D. Co-Founder, Exec. VP of Projects & Member of Management Board 1972
Mr. Andreas Emmenegger E.M.B.A. Advisor 1966
Mr. Alexander Zurcher COO & Member of Management Board NA
Dr. Nicolas Leupin M.B.A., Ph.D., M.D., MBA Chief Medical Officer & Member of Management Board 1973
Ms. Renate Gloggner Exec. VP of People & Community and Member of Management Board NA
Mr. Daniel Steiner Ph.D. Sr. VP of Research NA
Mr. Seth D. Lewis Sr. VP of Investor Relations, Communications & Strategy NA
Mr. Michael Pitzner Gen. Counsel, Compliance Officer & Sr. VP of Legal NA
Mr. Thomas Schwerzmann VP of HR NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions